# Evaluate the Safety and Efficacy of Xiyanping in Pediatric Participants With Severe Influenza-Like Symptoms

> **NCT03947411** · NA · UNKNOWN · sponsor: **Jiangxi Qingfeng Pharmaceutical Co. Ltd.** · enrollment: 72 (estimated)

## Conditions studied

- Severe Influenza

## Interventions

- **DRUG:** Oseltamivir Phosphate
- **DRUG:** Xiyanping injection+Oseltamivir Phosphate

## Key facts

- **NCT ID:** NCT03947411
- **Lead sponsor:** Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-03-04
- **Primary completion:** 2020-03-31
- **Final completion:** 2020-03-31
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2019-05-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03947411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03947411, "Evaluate the Safety and Efficacy of Xiyanping in Pediatric Participants With Severe Influenza-Like Symptoms". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT03947411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*